07:37 AM EST, 11/04/2024 (MT Newswires) -- TG Therapeutics ( TGTX ) reported Q3 earnings Monday of $0.02 per diluted share, down from $0.73 a year earlier.

Analysts polled by Capital IQ expected $0.03.

Revenue for the quarter ended Sept. 30 was $83.9 million, down from $165.8 million a year earlier.

Analysts surveyed by Capital IQ expected $81.7 million.

For 2024, the company said it now expects Briumvi US net product revenue of $300 million to $305 million, compared with the prior guidance of $290 million to $300 million. Analysts polled by Capital IQ expect $327.8 million in revenue.

As of Sept. 30, the company said it had $341 million in cash, cash equivalents and investment securities, which it expects could fund operations through its current operating plan.

Price: 23.60, Change: -3.30, Percent Change: -12.27